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ABSTRACT 
BACKGROUND and OBJECTIVES: To assess thromboembolic and bleeding risks in 
patients with heart failure (HF) and atrial fibrillation (AF) according to HF type. 
METHODS: We analyzed 6,170 AF patients from the Prevention of thromboembolic events 
- European Registry in Atrial Fibrillation (PREFER in AF), and categorized patients into: HF 
with reduced left-ventricular ejection fraction (HFrEF; LVEF<40%); mid-range EF (HFmrEF; 
LVEF: 40-49%); lower preserved EF (HFLpEF; LVEF: 50-60%), higher preserved EF 
(HFHpEF; LVEF>60%), and no HF. Outcomes were ischemic stroke, major adverse 
cardiovascular and cerebral events (MACCE) and major bleeding occurring within 1-year. 
RESULTS: The annual incidence of stroke was linearly and inversely related to LVEF, 
increasing by 0.054% per each 1% of LVEF decrease (95% CI: 0.013%-0.096%; p=0.031). 
Patients with HFHpEF had the highest CHA2DS2-VASc score, but significantly lower stroke 
incidence than other HF groups (0.65%, compared to HFLpEF 1.30%; HFmrEF 1.71%; 
HFrEF 1.75%; trend p=0.014). The incidence of MACCE was also lower in HFHpEF (2.0%) 
compared to other HF groups (range: 3.8-4.4%; p=0.001). Age, HF type, and NYHA class 
were independent predictors of thromboembolic events. Conversely, major bleeding did not 
significantly differ between groups (p=0.168).  
CONCLUSION: Our study in predominantly anticoagulated patients with AF shows that, 
reduction in LVEF is associated with higher thromboembolic, but not higher bleeding risk. 
HFHpEF is a distinct and puzzling group, featuring the highest CHA2DS2-VASc score but 
the lowest residual risk of thromboembolic events, which warrants further investigation.  
Key words: atrial fibrillation; heart failure; stroke; ejection fraction; bleeding. 
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Meeting in AF, TEAM in AF, funded and sponsored by Daiichi-Sankyo Europe.  
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INTRODUCTION 
Heart failure (HF) is a clinical syndrome caused by structural and/or functional 
cardiac abnormalities, which results in reduced cardiac output and/or elevated intracardiac 
pressures [1]. In recent times, HF has been classified broadly into two groups, mainly based 
on the measurement of left ventricular ejection fraction (LVEF): HF with reduced EF (HFrEF, 
EF<50) and HF with preserved EF (HFpEF, EF >50) [1, 2]. It has been estimated that 
approximately half of the patients with HF have HFpEF [2-6]. The European Society of 
Cardiology (ESC) has recently introduced a new subgroup of HF, defined as HF with mid-
range EF (HFmrEF, EF 40-49%). A main shortcoming of the recent HF classification is that 
current knowledge about HFpEF and HFmrEF is limited, and is based on evidence mostly 
derived from retrospective observational cohort studies or post-hoc analyses of randomized 
trials [1, 2].  
Atrial fibrillation (AF) and HF are tightly inter-connected entities [7-10]. Regardless of 
which condition arises first, the coexistence of these diagnoses confers substantially 
increased cardiovascular morbidity and mortality [11, 12]. HF and AF, jointly or in isolation, 
are likely to dominate the next era in cardiovascular disease epidemiology, in terms of 
prevalence, incidence, morbidity, mortality and healthcare expenditure [13-16]. Therefore, 
understanding predictors of outcome in AF patients according to different HF subtypes is of 
major clinical importance. Furthermore, the new reclassification of HF types introduced in 
the 2016 ESC guidelines [1] calls for a reappraisal of the thromboembolic and hemorrhagic 
risk stratification across different HF subtypes. To address these issues, we report on the 
HF sub-study of the Prevention of Thromboembolic Events European Registry in Atrial 
Fibrillation (PREFER in AF).  
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METHODS 
PREFER in AF was a prospective, real-world registry on 7,228 AF patients from 461 
hospitals and 7 European countries (Austria, France, Germany, Italy, Spain, Switzerland 
and the United Kingdom). Inclusion criteria were: age ≥18 years; at least one episode of AF 
in the previous one year, as demonstrated by an electrocardiogram or by an implanted 
pacemaker/defibrillator; and signed informed consent to be part of the study, mostly 
conducted in cardiology centers [17]. The first patient was included in January 2012, with 
the last follow-up visit being performed in January 2014. There were no explicit exclusion 
criteria. The study design included a baseline visit at the time of patient recruitment, and a 
clinical follow-up evaluation at 1 year. In this investigation we only included patients with 
data available from both the baseline and the 1-year follow-up visits. Only documented 
events were considered as relevant outcome measures, with any event occurring after the 
baseline assessment. The study design has been published [17, 18] and the protocol was 
approved by each local-site Ethics Committee. The registry was sponsored by Daiichi 
Sankyo Europe GmbH (Munich, Germany) via a contract research organization (SSS 
International Clinical Research GmbH – Munich, Germany) coordinating various local 
national contract research organizations.  
Definitions and endpoints 
The primary efficacy endpoint of this analysis was ischemic stroke. Secondary 
endpoints were i) the composite of major adverse cardiovascular and cerebral events 
(MACCE: stroke, systemic embolism, myocardial infarction and acute coronary syndrome), 
ii) the composite of thromboembolic events (stroke/transient ischemic attack (TIA)/arterial 
embolism (AE)), iii) death and iv) major bleeding occurring within 1 year of follow-up.  
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Stroke was defined as the abrupt onset of a focal neurologic deficit, generally 
distributed in the territory of a single brain artery (including the retinal artery), and not 
attributable to an identifiable non-vascular cause (i.e., brain tumor or trauma). The deficit 
had to be either characterized by symptoms lasting >24 hours or causing death within 24 
hours of symptom onset. The stroke definition used in the ENGAGE-AF TIMI 48 study and 
in our study reflects the Statement for Healthcare Professionals From the American Heart 
Association/American Stroke Association that incorporates the World Health Organization 
(WHO) definition of stroke [19]. TIA was defined as a focal neurologic deficit associated with 
symptoms lasting <24 hours.  
Systemic embolic event (SEE) was defined as an abrupt episode of arterial 
insufficiency with clinical or radiologic documentation of arterial occlusion in the absence of 
other likely mechanisms (e.g., atherosclerosis, instrumentation); venous thromboembolism 
and pulmonary embolism were also included in this outcome measure. 
Acute coronary syndrome was defined as a myocardial infarction or unstable angina. 
Myocardial infarction (MI) was defined according to the latest version of the Universal 
Definition [20]. Unstable angina was defined by specific clinical findings of prolonged (>20 
minutes) angina at rest; new onset of severe angina; angina that is increasing in frequency, 
longer in duration, or lower in threshold; or angina that occurs after a recent episode of MI, 
always in the absence of biochemical evidence of myocardial damage according to locally 
used troponin T or I tests [21].  
Major bleeding was defined as fatal bleeding and/or bleeding into a critical organ 
(intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or 
intramuscular with compartment syndrome) and/or clinically relevant bleeding with a 
hemoglobin drop ≥2 g/dL; this is consistent with the definition of major bleeding from the 
International Society on Thrombosis and Haemostasis [4].  
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HF definition and classification 
Treating physicians at the enrolling sites made a clinical diagnosis of HF (HF with 
reduced or preserved LVEF as per HF guidelines available at the time of inclusion), without 
any centralized adjudication of the diagnosis. Likewise, treating physicians included data on 
the EF, derived from echocardiography based on the Simpson´s method, without a 
centralized adjudication and verification. As a second step, we grouped patients with HF 
into HF with reduced EF (HFrEF; EF<40%); HF with mid-range EF (HFmrEF; EF: 40-49%); 
and HF with preserved ejection fraction (HFpEF; EF>50%), based on the most recent ESC 
guidelines [1]. Thirdly, as an exploratory analysis, we further subdivided the HFpEF cohort 
into HF with lower preserved ejection fraction (HFLpEF ; EF: 50-60%) and HF with higher 
preserved ejection fraction (HFHpEF; EF>60%).  
 
Statistics  
We here report categorical variables as absolute and percent frequencies (n, %). For 
each continuous variables, we report the mean, median, standard deviation or 95% 
confidence intervals (CI), as appropriate.  
We performed a complete case analysis and assumed that missing data were 
missing at random. We performed statistical comparisons with the t test, the Mann Whitney 
U test or the Chi2-test, as appropriate. We then calculated odds ratios (OR) for independent 
predictors of thromboembolic events in HF patients by multivariable logistic regression, 
where predictors and adjusting factors were included in the model. The composite of 
thromboembolic events (yes/no) was the dependent variable, whereas the following factors 
were included into the model as independent variables: EF, HF subtype 
(HFrEF/HFmrEF/HFLpEF/HFHpEF), LVEF per 10% decrease, New York Heart Association 
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(NYHA) class, anticoagulation treatment, CHA2D2VASc score (applied as indicated in the 
AF guidelines [22], where 1 point for congestive HF was given in patients with LV 
dysfunction and / or congestion at the time point of inclusion), body mass index (BMI), 
smoking. We report ORs, 95% confidence intervals (CIs) and the corresponding p value for 
such analyses.  
A post hoc power calculation has revealed a power of 84% for the comparison of the 
composite of MACCE event rates between the groups with a two-sided p value <0.05.  
All analyses are to be intended as descriptive/exploratory, and therefore no 
adjustment for multiple testing was done. All statistical analyses were performed using SAS, 
version 9.4 (Cary, North Carolina, USA), with a two-tailed significance value of 0.05. 
 
RESULTS 
The flow of patients through the PREFER in AF-HF substudy is shown in Figure 1. 
Out of 7,228 patients enrolled in the PREFER in AF Registry, 6,170 had baseline and 1-
year follow-up visits, complete data on the incidence of thromboembolic events, and 
information on the HF diagnosis. Of these, 4,571 had no HF and 1,599 had a HF diagnosis. 
Of these latter, 458 had HFrEF, 525 had HFmrEF and 616 had HFpEF. Among patients with 
HFpEF, 308 were classified with HFLpEF, and 308 with HFHpEF.  
The distributions of demographic and clinical features according to HF type are 
indicated in Tables 1 and 2. Among patients with HF, patients with HFrEF were more often 
male, smokers and with a younger age, more often with a history of vascular disease and of 
chronic kidney disease. In contrast, patients with HFHpEF were more often female, with a 
higher age and a higher mean systolic blood pressure as compared with other HF groups 
(Table 1).  
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We found the highest CHA2DS2-VASc score in patients with HFHpEF (mean 4.7) and 
the lowest in HFrEF (4.1) (p<0.0001; Table 2). Concordantly, 99% of HFHpEF patients had 
a clear indication for oral anticoagulation (OAC; CHA2DS2-VASc >2) compared with 95% in 
patients with HFrEF (p<0.001; Supplement Figure 1S; Table 2). The proportion of patients 
without OAC treatment despite indication (CHA2DS2-VASc >2) was lowest in the HFHpEF 
subgroup (6%) as compared to other HF subgroups (13% in each HFLpEF, HFmrEF and 
HFrEF, and 15% in no HF group; p=0.0004; Supplement Figure 1S). Of note, due to the 
time period in which PREFER in AF was performed, the penetration of NOACs was <10%, 
and was highest in HFHpEF as compared to other groups (9.4% in HFHpEF; 5.5% in 
HFLpEF; 5.5% in HFmrEF; 4.6% in HFrEF; p=0.026; Table 1). The frequency of 
paroxysmal AF was in the same range in HF patients (18-21%) and was highest in no HF 
patients (31%; p<0.001 for trend).  
Clinical outcomes 
Patients with any diagnosis of HF had a higher incidence of stroke as compared to 
patients without HF (1.3% vs 0.6% year; respectively; p=0.007). Despite the highest 
CHA2DS2-VASc score, the yearly incidence of stroke was only 0.65% in HFHpEF, 
significantly lower than in other HF subgroups (1.30% in HFLpEF; 1.71% in HFmrEF; 1.75% 
in HFrEF; p=0.014; Figure 2A), and increased by 0.054% per 1% of EF decrease (95% CI: 
0.013%-0.096%; p=0.031; Figure 2B). Also, in anticoagulated HF patients the incidence of 
ischemic stroke increased by 0.030% per each 1% of EF decrease (95% CI: 0.011%-
0.048%; p=0.003). Stroke incidence was comparable between HFHpEF and no-HF groups 
(Figure 2A; p=0.9746). 
Patients with any diagnosis of HF had a higher incidence of MACCE as compared to 
patients without HF (3.8% vs 2.1% per year; respectively; p<0.001). The yearly incidence of 
MACCE was lower in HFHpEF (2.0%) compared with other HF subgroups (4.2% in HFLpEF; 
Siller-Matula JM et al., page 9 
 
9 
 
3.8% in HFmrEF; 4.4% in HFrEF; p=0.001; Supplement Figure 2S). MACCE incidence 
was comparable between HFHpEF and no-HF groups (Supplement Figure 2S; p=0.9234). 
The incidence of major bleeding was higher in patients with HF as compared to 
patients without HF (3.6% vs 2.5% per year, respectively, p=0.01). There were no statistical 
differences in the incidences of the composite of major bleeding across the subgroups 
(trend p=0.161; Supplement Figure 3S). Of note, the incidence of major bleeding events 
according to bleeding type (intracranial bleeding (ICB), gastrointestinal (GI), other 
threatening major bleeding) was similar between HF groups, as well as in the entire study 
population (p>0.05; Supplement Table 1S).   
Patients with any diagnosis of HF had a higher incidence of death as compared to 
patients without HF (6.0% vs 1.9% year; respectively; p<0.001). Death rate increased with 
decreasing EF, and was highest in the HFrEF subgroup (HFrEF: 7.2%, HFmrEF:  6.5%, 
HFLpEF: 5.2%, HFHpEF: 4.2%, no HF: 1.9%; p<0.001). Death incidence was higher in 
patients with HFHpEF vs no-HF (p=0.005). 
There were no differences in the outcomes in respect to AF type in the overall 
population as well as there was no interaction between AF type, different HF subtypes and 
clinical outcomes (paroxysmal vs non-paroxysmal; p>0.05 for all comparisons). 
 
Predictors of thromboembolic risk in HF patients 
 The multivariable regression analysis identified 3 factors at baseline independently 
associated with thromboembolic events: HF subgroup (p=0.007), NYHA class (p<0.001) 
and age (p=0.029). Among different HF subgroups, the highest odds for the composite of 
thromboembolic events were in HFmrEF patients (OR: 3.10; 95% CI: 1.12-8.56). The 
following estimates were calculated for the NYHA class (OR per 1 increasing NYHA point: 
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2.92; 95% CI: 1.60-5.30) and age (OR per 1 year of age: 1.04; 95% CI: 1.00-1.08). While, 
as expected, the severity of HF symptoms (NYHA class III-IV) increased with decreasing EF 
(Supplement Figure 4S.A), NYHA classes III-IV (severe HF) were associated with a higher 
incidence of thromboembolic events as compared to NYHA classes I-II (mild to moderate 
HF), which was 12.3% and 12.5% in patients with HFmrEF and HFLpEF, respectively 
(p<0.05 for between group comparison; Supplement Figure 4S.B). 
 
Performance of the CHA2DS2-Vasc score in the prediction of stroke 
In patients with no HF the CHADS-VASc score >2 performed well in terms of 
prediction of stroke (OR: 1.70, 95%CI: 1.34-2.16, p<0.0001; AUC: 0.73, 95%CI: 0.62-0.83). 
In contrast, for HF patients its performance decreased with increasing HF severity. In the 
overall HF population the CHADS-VASc score >2 was not predictive of stroke (OR: 1.03, 
95%CI: 0.79-1.33, p=0.85; AUC: 0.50, 95%CI: 0.41-0.60). When each of the HF groups 
were analysed separately, the AUC for the CHADS-VASc score >2 decreased with the 
decreasing EF (HFHpEF AUC: 0.628, 95%CI: 0.03-1.00; HFLpEF AUC: 0.54, 95%CI: 0.36-
0.72; HFmrEF AUC: 0.46, 95%CI: 0.33-0.58; HFrEF AUC: 0.44, 95%CI: 0.25-0.62) and was 
predictive for stroke in none of the HF subgroups in the logistic regression model.   
 
Sensitivity analyses 
When patients without OAC treatment (ranging from 6% to 19% depending on the 
group) were excluded from each of the analyses, the magnitude and the direction of the 
estimates remained unchanged (data not shown).  
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DISCUSSION 
The central findings of the PREFER in AF – HF substudy investigating the 
association between HF type and thromboembolic events in this mainly anticoagulated 
cohort of AF patients in real-life clinical conditions under registry setting are as follows: i. the 
subtype of HF predicts the residual risk of thromboembolic events, with an inverse 
association between LVEF and hard thromboembolic endpoints, such as ischemic stroke 
and MACCE; ii. in HF patients, in addition to EF and age, the NYHA class is a strong and 
independent predictor of thromboembolic events; iii. HF patients with HFLpEF and HFHpEF 
represent quite distinct populations, which also differ in terms of thromboembolic risk; iv. 
mortality increases with decreasing EF, and was highest in the HFrEF subgroup. 
The definition of HFpEF is difficult, which can be illustrated by the various 
classifications proposed by experts and by disparate inclusion criteria of clinical trials [2], 
which led to heterogeneity of HFpEF patients recruited into most studies and registries. 
Such difficulties in classification also affect our study. Even for the key diagnostic criterion, 
EF, different cut-offs have been used across trials and registries on HFpEF (ranging from 
>40% to >55%), of which most were applied in a post-hoc manner [12]. The validity and 
reproducibility of estimating systolic and diastolic function in the context of AF has also been 
questioned [23]. Therefore, the available evidence addressing the issue of stroke risk 
among different HF subtypes, is based on studies using different inclusion and exclusion 
criteria, end point assessments, sample sizes, patient populations and characteristics. This 
is mirrored in the substantial statistical and clinical heterogeneity across studies [12]. Many 
such limitations also apply to our study, but still the present findings add important insights 
into the discussion on the risk of stroke in AF across HF subtypes.  
Although the prognosis of all patients with HF is poor, HFpEF has been postulated to 
be more benign as compared to HFrEF [8]. Indeed, considering the risk of 
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thromboembolism in the presence of AF, HFrEF was associated with the highest incidence 
of adverse events such as ischemic stroke, MACCE and death in our analysis, which 
confirms the findings of other prospective studies, such as the Studies of Left Ventricular 
Dysfunction (SOLVD), the Survival and Ventricular Enlargement (SAVE), the Northern 
Manhattan Study (NOMASS), or the Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trials [24-27], showing that EF is 
an independent risk factor for stroke or systemic embolism [28]. In contrast, several other 
studies as the Loire Valley Atrial Fibrillation Project [29], the Atrial Fibrillation Clopidogrel 
Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trial in patients not 
randomized to oral anticoagulation [30], or a meta-analysis of cohort studies and post-hoc 
sub-group analyses of randomized trials in AF patients indicated no difference in the risk of 
stroke between HFrEF vs HFpEF groups [12]. A possible explanation for these differences 
is the circumstance that in some studies patients were not or rarely anticoagulated and in 
the meta-analysis 50% of patients were anticoagulated [12], as compared to 90% in our 
study. Therefore, our study focused on the residual risk of stroke in the majority of our 
patients, and such residual risk is known to be affected by the type of AF and the presence 
of HF [31]. A third possible explanation for the inconsistent results between our study and 
the previous meta-analysis is the fact that the definitions of HFpEF were very heterogenous 
and applied only post-hoc for the majority of included studies [2, 12]. A key step that allowed 
more insightful information on the risk of stroke in the HFpEF population in our study was to 
subdivide such patients into HFLpEF and HFHpEF. 
In parallel with the risk of stroke, an association between HF subtypes and mortality 
has been previously described [12], indicating a 1.24-fold higher risk of death for HFrEF as 
compared with HFpEF. Thus, we confirm this finding in the PREFER in AF - HF substudy.  
A true central finding of the present analysis is the uniqueness of mainly 
anticoagulated AF patients with HFHpEF, apparently representing a distinct patient 
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population. Such patients are characterized by the highest CHA2DS2-VASc score, but also, 
surprisingly, by the lowest incidence of thromboembolic events. This association was also 
confirmed after exclusion of patients without a proper anticoagulant treatment. Furthermore, 
it is crucial to note that splitting the HFpEF into two groups, those with HFLpEF and 
HFHpEF, revealed a statistically significant difference in the rate of thromboembolic events 
between such groups. Indeed, the incidence of ischemic stroke or MACCE was half in 
HFHpEF compared with HFLpEF. Therefore, distinguishing a group of HFHpEF in our study 
might underline the complex pathophysiology and heterogeneity of the HFpEF syndrome. In 
contrast, we have found no significant differences in the rates of thromboembolic events 
between HFrEF and HFmrEF.  
Guidelines encourage the use of the CHA2DS2-VASc score only for the decision 
making on initiation of anticoagulant treatment in AF patients [22]. Patients with a 
CHA2DS2-VASc score of >2, represent 85% of AF population being at moderate-to-high 
risk of thrombotic events, and who should benefit from anticoagulation. Importantly, the 
CHA2DS2-VASc score has never been established and is not recommended as a tool for 
predicting thromboembolism in patients already on anticoagulation, as it was the case in 
90% of patient population included in this study. Interestingly, CHA2DS2-VASc score 
predicted stroke only in patients without HF in our study. In patients with HF irrespectively of 
the HF subtype, CHA2DS2-VASc score was not a predictor of residual risk of stroke. 
Moreover, the performance of CHA2DS2-VASc score to predict stroke in anticoagulated HF 
patients decreased with decreasing EF, which might confirm our results that EF is strongly 
associated with a residual risk of stroke in HF patients.    
It has been reported that measures of cardiac performance, such as the LVEF, 
correlate poorly with HF symptoms (e.g., NYHA class) [32]. Accordingly, some patients with 
HFrEF may be asymptomatic, whereas some patients with HFpEF may have severe 
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dyspnea, as also demonstrated in our analysis. Our study, however, also showed that 
NYHA functional class was associated with thromboembolic events, independent of the HF 
type and other factors, increasing the odds for thromboembolism by 2.9 per 1 increasing 
NYHA point. Our observation that the clinical severity of HF in AF has independent and 
direct prognostic implications, confirms previous findings in the overall HF population [28]. 
Concordantly, the incidence of stroke was 3-fold higher in patients with more severe HF 
(median NYHA class 3.4) in the Prospective Randomized Milrinone Survival trial (PROMISE 
trial) as compared to patients with mild HF (median NYHA class 1.7) in the Studies of Left 
Ventricular Dysfunction (SOLVED trial) [33]. 
 Importantly, our study design differs from a number of previously published studies 
on association between HF type and AF. Whereas in our analysis all patients had AF and 
39% were also diagnosed with HF, other studies focused on patients who all had been 
diagnosed with HF, and some had also AF (prevalence ranging from 17% to 65%) [34-36]. 
Based on this assumption, we tested the incidence of thromboembolism in AF patients 
according to HF diagnosis and type. In contrast, other analyses focused on thromboembolic 
risk in HF patients according to rhythm disorder: AF vs no AF. Whereas results of both 
types of studies yield complementary information, such analyses are not interchangeable 
and a direct comparison of results is not feasible.  
 
Study strengths and limitations 
The strengths of our study include its focus on different types of HF, including the 
recent HF classification by the ESC, the large number (>6,000) of patients included, 
complete 1-year follow-up data on the incidence of thromboembolic events, and detailed 
sensitivity analyses with a focus on a new group of HFHpEF. Our study also adds data on 
the distribution of OAC use between the HF groups, predictors of thromboembolic events, 
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and the incidence of hard ischemic outcomes (such as ischemic stroke and MACCE) in 
each of the HF groups, as well as in relation to EF.  
A major shortcoming of this study is the fact that the HF diagnosis (HFrEF or HFpEF, 
based on the available guidelines at the time of inclusion) was made by a treating physician 
at the study site and was not independently verified or adjudicated. Moreover, diagnostic 
criteria for HF changed over time. Due to the missing data on the levels of the brain 
natriuretic peptides (BNP), we could not verify the HF diagnosis. However, we performed a 
sensitivity analysis for a subgroup of patients with HFmrEF and HFpEF and available 
echocardiographic data recommended by the current guidelines for the HF diagnosis (left 
atrial enlargement, left ventricular hypertrophy), which confirmed the direction and the 
magnitude of the main study estimates. A second major shortcoming is here the use of 
echocardiographic assessment of the EF, known to be quite variable among operators and 
even within the single operator [37]. Additionally, we are lacking information whether 
adjustment for heart rate at the time of echo was performed, which might also influence the 
assessment of EF. EF derived by echocardiography with the modified Simpson formula was 
reported by the investigators and was not adjudicated. Much more accurate estimates of the 
EF are provided by magnetic resonance imaging [38], but such data were not available. The 
registry also did not provide data on parameters of left ventricular volumes or diastolic 
function, which have been shown to be potentially valuable in AF patients [23]. Moreover, 
imaging modalities were not adjudicated to ensure uniformity. Therefore, our study certainly 
lacks the standardization of HF diagnosis and of the EF measurements, and there is a risk 
of residual confounding. The registry also did not provide information on the underlying 
disease leading to HF. Mortality data were provided by the study centers following the final 
completion of the study, so that such data might be incomplete. Additional limitation is that 
the distinction between the two categories of HF with pEF (HFHpEF and HFLpEF) was a 
Siller-Matula JM et al., page 16 
 
16 
 
part of post-hoc exploratory analyses. We fully acknowledge such limitations. This is 
however the first report in the literature describing a possible heterogeneity in the risk of 
stroke and bleeding within the broad category of patients with preserved EF, and calls for an 
independent validation of such data in independent cohorts. 
 
CONCLUSION 
In mainly anticoagulated patients with AF, the subtype of HF predicts the 
thromboembolic risk: patients with HFHpEF apparently represent a distinct patient 
population, with the highest CHA2DS2-VASc score but the lowest incidence of 
thromboembolic events. AF with HFrEF is associated with most severe adverse events, 
such as ischemic stroke and MACCE. HFHpEF with AF had a comparable thromboembolic 
risk to controls without HF but relatively high risk of bleeding. If independently confirmed, 
HFHpEF should be further inspected in future studies as possibly distinct from HFLpEF. 
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TABLES: 
Table 1. Patient demographic data according to heart failure subgroups. 
  HFrEF HFmEF HFLpEF  HFHpEF  no HF 
p 
between 
HF 
groups 
N 458 525 308 308 4571 
 
Age (years)  72 73 75 76 71 <0.0001 
BMI 27.4 28.0 27.9 28.1 28.0 0.0926 
Male (%) 76 67 59 45 59 <0.0001 
Smoking  (%) 49 46 38 31 39 <0.0001 
Prior stroke  (%) 10 11 10 8 8 0.7993 
Coronary heart disease (%) 46 41 39 27 18 <0.0001 
Prior stenting (%)  24 17 11 11 8 <0.0001 
Prior myocardial infarction (%) 29 22 16 8 7 <0.0001 
Peripheral arterial disease (%)  7.4 7.6 7.9 5.0 3.5 0.4515 
Chronic kidney disease (%)  29 16 20 22 10 <0.0001 
Chronic obstructive pulmonary 
disease (%) 19 17 22 16 9 0.1189 
Systole blood pressure (mmHg) at 
baseline (mean) 123 130 129 133 133 <0.0001 
Diastolic blood pressure (mmHg) at 
baseline (mean) 74 78 76 76 78 <0.0001 
Heart rate (beats/min) at baseline 
(mean) 82 81 80 78 78 0.0180 
Prior major bleeding event (%) 5.2 3.8 9.1 7.5 3.4 0.0096 
HASBLED score (mean) 2.3 2.2 2.5 2.3 1.9 0.0696 
Paroxysmal AF (%) 17.9 21.0 21.1 19.2 33.8  0.6090 
Valvular heart disease (moderate or 
severe) 35.2 26.9 26.6 24.0 13.3 0.0027 
Antithrombotic therapies (%):  
           No therapy 3.7 4.6 4.6 2.9 6.7 0.6336 
     Oral anticoagulant (VKA or VKA &   
     antiplatelet or NOAC) 88 87 88 94 81 0.0189 
     VKA 65 67 75 75 66 0.0027 
     VKA plus antiplatelet 18.6 13.1 7.5 9.1 8.9 <0.0001 
     NOAC  4.6 5.5 5.5 9.4 6.1 0.0397 
     NOAC plus antiplatelet 0.7 1.5 0.7 1.3 1.1 0.4847 
     Antiplatelet only 8.5 8.2 7.8 3.3 12.6 0.0261 
Legend: HFrEF: heart failure with reduced ejection fraction; HFmrEF: HF with mid-range EF: HFLpEF: HF with 
lower preserved ejection fraction; HFHpEF : HF with higher preserved ejection fraction; BMI: body mass index; 
NOAC: non-vitamin K oral anticoagulants; VKA: vitamin K oral anticoagulants; TIA: transient ischemic attack. 
Data are presented as n, mean or percentages as appropriate. p value for trend.   
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Table 2. Mean CHA2DS2-VASc score and its components according to heart failure 
subgroups. 
   HFrEF HFmEF HFLpEF  HFHpEF  no HF 
p between 
HF groups 
CHA2DS2-VASc score 4.1 4.4 4.5 4.7 3.0 <0.0001 
Points 0 (%)  0 0 0 0 6.6 0.2458 
Points 1 (%)  4.9 5.4 1.7 1 12.9 0.0007 
Points >2 (%) 95.1 94.6 98.3 99.0 80.5 0.0016 
Congestive heart failure (%) 100 100 96.0 94.3 0.0 <0.0001 
Hypertension (%) 65.9 71.4 80.4 79.3 71.2 <0.0001 
Age 65–74 years (%) 33.7 30.9 30.4 26.7 33.9 0.2395 
Age ≥ 75 years (%) 43.5 49.7 56.6 63.0 41.9 <0.0001 
Diabetes mellitus (%) 26.4 31.6 29.6 32.3 19.1 0.2437 
Prior stroke/TIA/ 
thromboembolic event (%) 16.2 18.8 15.5 15.7 15.2 0.5302 
Vascular disease (%) 43.7 33.3 30.1 25.3 17.5 <0.0001 
Female gender (%) 23.7 33.7 40.1 55.3 40.9 <0.0001 
Legend: HFrEF: heart failure with reduced ejection fraction; HFmrEF: HF with mid-range EF: HFLpEF: HF with 
lower preserved ejection fraction; HFHpEF : HF with higher preserved ejection fraction; TIA: transient ischemic 
attack. p value for trend.   
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FIGURES 
 
Figure 1. Flow of patients in the PREFER in AF – HF substudy. HFrEF: heart failure with 
reduced ejection fraction; HFmrEF: HF with mid-range EF; HFpEF: HF with preserved 
ejection fraction; HFLpEF: HF with lower preserved ejection fraction; HFHpEF: HF with 
higher preserved ejection fraction.  
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Figure 2. A) Annual incidence (mean and 95% confidence intervals, (CI)) of ischemic 
stroke; p value for trend; B) Linear regression model for the association between the 
incidence of ischemic stroke and ejection fraction (EF).  
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